Opinion: $2 million gene therapies demand new financing infrastructure, not new science
A STAT News commentary argues that the bottleneck for transformative gene therapies is no longer biological but financial, calling for structural reform in how payers and health systems fund one-time curative treatments.
Writing in STAT News, William Padula, a health economist, argues that the principal obstacle to patients benefiting from approved gene therapies is not a lack of efficacious treatments but a lack of infrastructure to fund and deliver them. With single-administration gene therapies now priced at or above $2 million in the United States, conventional insurance and Medicaid payment models — designed for recurring drug expenditures — are poorly suited to treatments where the cost is incurred once but the benefit accrues over a lifetime.
Padula's commentary surveys proposed alternatives, including annuity-style outcome-based contracts, subscription or 'Netflix' models under which payers purchase access to a portfolio of therapies, and public reinsurance mechanisms. Each carries tradeoffs around risk allocation between manufacturers, payers, and government programmes.
The piece does not address specific genetic conditions or patient populations in clinical detail, but the financing question is directly relevant to rare-disease genetics research, genetic counselling practice, and health-policy education. As gene-therapy pipelines mature — particularly for haemoglobinopathies, inherited metabolic disorders, and rare neuromuscular conditions — the payment architecture will shape which populations can access approved products.
The commentary is an opinion piece and does not present primary research data.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Gene therapies are medicines that aim to treat or cure a disease by changing or replacing faulty genes, often in a single treatment. Some of these therapies now cost around $2 million per patient in the United States. A health economist writing in STAT News argues that the main reason many patients cannot access these treatments is not that the science is unready, but that health systems and insurance programmes were not built to pay for treatments that cost this much in one go.
The article explores ideas such as spreading payments over time or creating new government-backed insurance schemes. These are proposals, not current policy. The findings discussed apply to health systems in the United States; arrangements in the UK, where the NHS negotiates access separately, differ.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-06-08Opinion: $2 million gene therapy cures require a financing model